

10th Annual Gastroenterology & Hepatology Symposium

--
February 2-3, 2018 • Anaheim, CA



Optimizing biologic therapies in IBD

Sandra S Park, MD
Assistant Professor of Medicine
Department of Gastroenterology

Outline

- Medical therapy treatment endpoints
- Biologic Therapy in IBD
- Mechanisms for Loss of Response to Biologics
- Strategies for optimizing use of anti-TNF therapy

Why do we care about drug optimization?

Biologic Therapy in IBD

Current Biologics Available

Name	Primary target	FDA-approved indication
Infliximab (Remicade [®])	TNF	CD, UC
Adalimumab (Humira [®])	TNF	CD, UC
Certolizumab (Cimzia [®])	TNF	CD
Golimumab (Simponi [®])	TNF	UC
Natalizumab (Tysabri [®])	alpha-4 integrin	CD
Vedolizumab (Entyvio [®])	alpha-4-beta-7 integrin	CD, UC
Ustekinumab (Stelara [®])	IL-12/23	CD

Loss of Response to Biologics

Strategies for optimizing use of biologics

Treat Early in Disease

Immunogenicity

Enhanced Drug Clearance & Accelerated Dosing

Accelerated Infliximab

Algorithm for drug monitoring

Therapeutic Drug Monitoring – Be Proactive

Thank You